Skip to main content

Venture the Path Less TraveledTM

A healthcare venture capital firm rooted in the Midwest

Arboretum Ventures icon

Improving patient outcomes and access, reducing healthcare costs

Our progressive strategy of investing in under-ventured geographies and sectors, coupled with our expertise in building deep relationships with entrepreneurs, executives, and investment partners across the healthcare industry, are significant factors contributing to our success.

View our portfolio
medical devices icon
Medical Devices
life science tools icon
Life Science Tools
& Diagnostics
tech-enabled care delivery icon
Tech-Enabled
Care Delivery
pharma adjacencies icon
Pharma
Adjacencies

Entrepreneurs

We seek innovations that solve (big) healthcare problems and make a transformational impact from teams who are diverse in thought, geography, and demographics.

Investors

We have a proven formula for identifying early-stage startups that can create value in a capital-efficient manner, accelerate portfolio value, and deliver superior returns.

Portfolio Spotlight

We invest in today’s ideas to forge a path for better healthcare tomorrow

Where NeuMoDx started?
Molecular diagnostics is one of the fastest-growing segments within the in-vitro diagnostics market, but existing systems are expensive, complex, and lack sophisticated automation. Through a unique combination of automation and microfluidics, the NeuMoDx Molecular clinical PCR systems offer best-in-class ease of use, throughput, and cost per test.

Where NeuMoDx is today?
Arboretum collaborated with the team to set the strategic direction that helped accelerate the company’s product development timeline and helped recruit new investors. Since Arboretum’s investment, NeuMoDx gained regulatory approvals for its first assays, launched its product, and in September 2020, QIAGEN acquired NeuMoDx to strengthen its portfolio of automated molecular testing.

Ready to grow with us?
laboratory scientists
NewMoDX logo

We fuel the future of healthcare

700M+
under management across five funds
75
of the portfolio invested in under-ventured markets over 20 years
48
of all active companies have either a female / minority CEO or founder
10
patient - lives impacted
View portfolio

Shifting the venture capital paradigm

We are proud to be a Midwest venture capital firm operating with transparency, integrity, and approachability to help you realize your entrepreneurial and investor goals. Together, we’ll positively impact patients, communities, and healthcare.

Meet your team
Arboretum Ventures team

Testimonials

Tim Petersen brings a wealth of healthcare expertise and relationships to our company and is a very effective member of our Board of Directors. He rolls up his sleeves to assist us when it’s truly needed and has the good sense to stay out of the way when it’s not.

Lou SilvermanCEO Hicuity Health

As our Chairman, Paul McCreadie’s integrity, character, and talent creates a solid foundation of trust, which is essential for effective strategic thinking and decision making. I know that whether things are going well, or if we are facing challenges, I can always count on his collaborative, shoulder to shoulder support and entrepreneurial insight.

Mark ForchetteCEO Delphinus Medical Technologies

Jan Garfinkle has been a valued partner since the early formation of Strata. Her reputation in the business and deep network helped us attract an experienced syndicate of investors and has opened doors to strategic partners vital for our success.

Dan RhodesCEO Strata Oncology

Arboretum Ventures understands the importance of collaboration and passion in building a great company. Their expertise in clinical and reimbursement strategy along with a broad industry network were invaluable in fostering our success.

Surbhi SarnaCEO nVision Medical

Tom Shehab and the supporting Arboretum team provided not only the capital we needed, but also strategic advice, access to an extensive network of potential partners, and unceasing encouragement. Their support has brought out the best in our team and allowed us to focus on our vision of making neuromodulation therapies accessible and easier to use for millions of patients worldwide.

Jill SchiaparelliCEO Avation Medical

In the News

September 30, 2022 in Delphinus, Home Page, News Page

Delphinus Raises $30 Million in Series D Funding to Transform Dense Breast Screening

Delphinus Medical Technologies, Inc. today announced the closing of a $30 million Series D financing to fuel worldwide commercialization of its SoftVue™ 3D Whole Breast Ultrasound Tomography System (SoftVue™). The round drew…
Read More
September 27, 2022 in Francis Medical, News Page

Francis Medical Included as One of Ten Medical Device Startups You Need To Know

Francis Medical has developed the Vanquish System, a minimally invasive transurethral prostate ablation device that uses water vapor to kill cancer cells.
Read More
September 27, 2022 in Delphinus, News Page

Karmanos Cancer Institute first to receive innovative, FDA-approved SoftVue™ Breast Imaging System

The Barbara Ann Karmanos Cancer Institute, the world-renowned, Detroit-based National Cancer Institute-Designated Comprehensive Cancer Center, is the first to receive the SoftVue™ 3D Whole Breast Ultrasound Tomography System (SoftVue™), following its approval by the…
Read More